{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T05:05:18Z","timestamp":1648703118993},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.arteri.2018.04.002","type":"journal-article","created":{"date-parts":[[2018,5,19]],"date-time":"2018-05-19T17:48:18Z","timestamp":1526752098000},"page":"188-192","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Los fibratos en la prevenci\u00f3n primaria de la enfermedad cardiovascular. Comentarios a los resultados de una revisi\u00f3n sistem\u00e1tica de la Colaboraci\u00f3n Cochrane"],"prefix":"10.1016","volume":"30","author":[{"given":"Angel","family":"Brea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Mill\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan F.","family":"Ascaso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Hern\u00e1ndez-Mijares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Mantilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C.","family":"Pedro-Botet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Pint\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.arteri.2018.04.002_bib0135","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1097\/01.hjr.0000277984.31558.c4","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: Full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice","volume":"14","author":"Graham","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.arteri.2018.04.002_bib0140","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11936-011-0128-7","article-title":"The use of fibric acid derivatives in cardiovascular prevention","volume":"13","author":"Khoury","year":"2011","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.arteri.2018.04.002_bib0145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0889-8529(18)30324-4","article-title":"Acquired hyperlipidemia (secondary dyslipoproteinemias)","volume":"19","author":"Chait","year":"1990","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.arteri.2018.04.002_bib0150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0025-7125(16)30179-1","article-title":"Secondary causes of hyperlipidemia","volume":"78","author":"Stone","year":"1994","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.arteri.2018.04.002_bib0155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/01.CIR.75.1.124","article-title":"The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease","volume":"75","author":"Steiner","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2018.04.002_bib0160","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","article-title":"Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)","volume":"316","author":"Turner","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.arteri.2018.04.002_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.CIR.95.1.1","article-title":"Small LDL, atherogenic dyslipidemia, and the metabolic syndrome","volume":"95","author":"Grundy","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2018.04.002_bib0170","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11883-004-0104-8","article-title":"The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy","volume":"6","author":"Fazio","year":"2004","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.arteri.2018.04.002_bib0175","doi-asserted-by":"crossref","first-page":"962.e1","DOI":"10.1016\/j.amjmed.2009.03.030","article-title":"Effect of fibrates on lipid profiles and cardiovascular outcomes: A systematic review","volume":"122","author":"Abourbih","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.arteri.2018.04.002_bib0180","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2018.04.002_bib0185","unstructured":"Department of Economic and Social Affairs. Consolidated list of products whose consumption and\/or sale have been banned, withdrawn, severely restricted or not approved by governments. Eighth Issue, Pharmaceuticals. New York: United Nations; 2003."},{"key":"10.1016\/j.arteri.2018.04.002_bib0190","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/hrt.42.3.370","article-title":"A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate","volume":"42","author":"Miettinen","year":"1979","journal-title":"Br Heart J"},{"key":"10.1016\/j.arteri.2018.04.002_bib0195","article-title":"Fibrates for primary prevention of cardiovascular disease events","volume":"11","author":"Jakob","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arteri.2018.04.002_bib0200","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: Meta-analysis of randomised controlled trials including 117,411 patients","volume":"349","author":"Keene","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.arteri.2018.04.002_bib0205","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2018.04.002_bib0210","first-page":"1849","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus","volume":"365","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2018.04.002_bib0215","unstructured":"Sch\u00fcnemann H, Brozek J, Guyatt G, Oxman A, editors. GRADE Handbook [consultado 15 Nov 2016]. Disponible en: http:\/\/gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"key":"10.1016\/j.arteri.2018.04.002_bib0220","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/archinte.165.7.725","article-title":"Effect of different antilipidemic agents and diets on mortality: A systematic review","volume":"165","author":"Studer","year":"2005","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.arteri.2018.04.002_bib0225","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2008.11.211","article-title":"Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus\u2013A pooled meta-analysis of randomized placebo-controlled clinical trials","volume":"141","author":"Saha","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.arteri.2018.04.002_bib0230","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2018.04.002_bib0235","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.CIR.85.1.37","article-title":"Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment","volume":"85","author":"Manninen","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2018.04.002_bib0240","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMc1006407","article-title":"Combination lipid therapy in type 2 diabetes","volume":"363","author":"Sacks","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2018.04.002_bib0245","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2018.04.002_bib0250","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: A systematic review and meta-analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.arteri.2018.04.002_bib0255","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2018.04.002_bib0260","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916818300500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916818300500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T03:16:47Z","timestamp":1571368607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916818300500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0214916818300500"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2018.04.002","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Los fibratos en la prevenci\u00f3n primaria de la enfermedad cardiovascular. Comentarios a los resultados de una revisi\u00f3n sistem\u00e1tica de la Colaboraci\u00f3n Cochrane","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2018.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}